Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 4 Interventional Results available

Abacavir/Lamivudine Versus Emtricitabine/Tenofovir Both In Combination With Lopinavir/Ritonavir For The Treatment Of HIV

ClinicalTrials.gov ID: NCT00244712

Public ClinicalTrials.gov record NCT00244712. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 22, 2026, 9:13 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A 96-Week, Phase IV, Randomized, Double-Blind, Multicenter Study of the Safety and Efficacy of EPZICOM Versus TRUVADA Administered in Combination With KALETRA in Antiretroviral-Naive HIV-1 Infected Subjects

Study identification

NCT ID
NCT00244712
Recruitment status
Completed
Study type
Interventional
Phase
Phase 4
Lead sponsor
GlaxoSmithKline
Industry
Enrollment
688 participants

Conditions and interventions

Conditions

Interventions

  • emtricitabine/tenofovir Drug
  • abacavir/lamivudine Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jun 30, 2005
Primary completion
Mar 31, 2008
Completion
Mar 31, 2008
Last update posted
Jun 7, 2010

2005 – 2008

United States locations

U.S. sites
72
U.S. states
22
U.S. cities
55
Facility City State ZIP Site status
GSK Investigational Site Phoenix Arizona 85006
GSK Investigational Site Phoenix Arizona 85012
GSK Investigational Site Tucson Arizona 85745
GSK Investigational Site Beverly Hills California 90210
GSK Investigational Site Fountain Valley California 92708
GSK Investigational Site Garden Grove California 92845
GSK Investigational Site Long Beach California 90813
GSK Investigational Site Los Angeles California 90069
GSK Investigational Site Newport Beach California 92663
GSK Investigational Site Oakland California 94602
GSK Investigational Site Oakland California 94609
GSK Investigational Site Denver Colorado 80204
GSK Investigational Site Denver Colorado 80205
GSK Investigational Site Denver Colorado 80220
GSK Investigational Site Glastonbury Connecticut 06033
GSK Investigational Site Norwalk Connecticut 06851
GSK Investigational Site Washington D.C. District of Columbia 20007
GSK Investigational Site Washington D.C. District of Columbia 20009
GSK Investigational Site Washington D.C. District of Columbia 20037
GSK Investigational Site Fort Lauderdale Florida 33306
GSK Investigational Site Fort Lauderdale Florida 33308
GSK Investigational Site Fort Lauderdale Florida 33316
GSK Investigational Site Fort Myers Florida 33901
GSK Investigational Site Key West Florida 33040
GSK Investigational Site Miami Florida 33136
GSK Investigational Site Plantation Florida 33317
GSK Investigational Site Port Saint Lucie Florida 34952
GSK Investigational Site Sarasota Florida 34239
GSK Investigational Site Sarasota Florida 34243
GSK Investigational Site Tampa Florida 33602
GSK Investigational Site Tampa Florida 33614
GSK Investigational Site Atlanta Georgia 30308/30309
GSK Investigational Site Atlanta Georgia 30308
GSK Investigational Site Atlanta Georgia 30339
GSK Investigational Site Augusta Georgia 30912
GSK Investigational Site Decatur Georgia 30033
GSK Investigational Site Chicago Illinois 60612
GSK Investigational Site Chicago Illinois 60637
GSK Investigational Site Chicago Illinois 60657
GSK Investigational Site Maywood Illinois 60153
GSK Investigational Site Lexington Kentucky 40536
GSK Investigational Site Louisville Kentucky 40202
GSK Investigational Site Baltimore Maryland 21201
GSK Investigational Site St Louis Missouri 63108
GSK Investigational Site Las Vegas Nevada 89102
GSK Investigational Site Hillsborough New Jersey 08844
GSK Investigational Site Newark New Jersey 07102
GSK Investigational Site Somers Point New Jersey 08244
GSK Investigational Site New York New York 10011
GSK Investigational Site New York New York 10065
GSK Investigational Site Rochester New York 14604
GSK Investigational Site Charlotte North Carolina 28209
GSK Investigational Site Greenville North Carolina 27834
GSK Investigational Site Toledo Ohio 43614
GSK Investigational Site Portland Oregon 97219
GSK Investigational Site Philadelphia Pennsylvania 19140
GSK Investigational Site West Reading Pennsylvania 19611
GSK Investigational Site Columbia South Carolina 29206
GSK Investigational Site Austin Texas 78751
GSK Investigational Site Dallas Texas 75208
GSK Investigational Site Dallas Texas 75246
GSK Investigational Site Fort Worth Texas 76104
GSK Investigational Site Harlingen Texas 78550
GSK Investigational Site Houston Texas 77027
GSK Investigational Site Houston Texas 77030
GSK Investigational Site Longview Texas 75604
GSK Investigational Site Tyler Texas 75708
GSK Investigational Site Annandale Virginia 22003
GSK Investigational Site Charlottesville Virginia 22908
GSK Investigational Site Hampton Virginia 23666
GSK Investigational Site Lynchburg Virginia 24501
GSK Investigational Site Milwaukee Wisconsin 53226

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 2 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00244712, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jun 7, 2010 · Synced Jul 22, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00244712 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →